Süleyman Caner Karahan

Süleyman Caner Karahan

Auto-generated profile, based on publicly available information

Süleyman Caner Karahan

Karadeniz Technical University, Faculty of Medicine, Department of Medical Biochemistry

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 December 2009 in European Surgical Research
Verified
Journal Article
Closed access
SKS. Caner Karahan
S. Caner Karahan
IKİsMail Koramaz
İsMail Koramaz
GAGökalp Altun
Gökalp Altun
UUUtku Uçar
Utku Uçar
MTMurat Topbaş
Murat Topbaş
MKMüge Kopuz
Müge Kopuz
Background: The aims of this preliminary study were to determine the alteration of serum ischemia-modified albumin (IMA) levels and to investigate whether IMA may be used as an indicator of the cardioprotective efficacy of N-acetylcysteine (NAC) in patients undergoing coronary bypass grafting (CABG). Patients and Methods: Forty-four patients were randomized into one of two groups on the basis of cardioplegic strategies, either cold-blood cardioplegia enriched with NAC (50 mg/kg) or cold-blood cardioplegia alone. Serum IMA, cardiac troponin T (cTnT) and malondialdehyde (MDA) levels determined in NAC-enriched patients before and after CABG were compared with those of the NAC-free group. The albumin cobalt binding assay was used for IMA determination. Results: Serum IMA levels were significantly elevated after cross-clamping and peaked at 6 h after reperfusion in the two groups. In NAC-enriched patients, IMA levels determined 6, 12, 24 and 48 h after reperfusion were significantly lower than those of the NAC-free group (p ≤ 0.001, p < 0.001, p < 0.001 and p < 0.001, respectively). IMA returned to baseline 24 h after reperfusion differently from cTnT and MDA in the NAC-enriched group. Conclusions: IMA may be used as not only an indicator of myocardial ischemia-reperfusion injury, but also as a useful indicator of the cardioprotective effect of NAC in CABG.

24 July 2019 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
SESercan Ergün
Sercan Ergün
DADiler Us Altay
Diler Us Altay
SGSezgin Gunes
Sezgin Gunes
RBRecep Büyükalpelli
Recep Büyükalpelli
SKSüleyman Caner Karahan
Süleyman Caner Karahan
ÜAÜmmet Abur
Ümmet Abur

20 September 2021 in Scandinavian Journal of Clinical and Laboratory Investigation
Verified
Journal Article
Closed access
HYHatice Bozkurt Yavuz
Hatice Bozkurt Yavuz
MBMehmet Akif Bildirici
Mehmet Akif Bildirici
HYHüseyin Yaman
Hüseyin Yaman
SKSüleyman Caner Karahan
Süleyman Caner Karahan
YAYüksel Aliyazıcıoğlu
Yüksel Aliyazıcıoğlu
AÖAsım Örem
Asım Örem
The use of measurement uncertainty among clinical laboratories becomes widespread. Measurement uncertainty can be reported with the result, as well as be used in certain reference change value (RCV) calculation equations. RCV is especially recommended for use in tests with a low individuality index. In our study, we calculated the measurement uncertainty of AFP, CA 125, CA 15-3, CA 19-9, CEA tumor markers with the ISO TS 20914:2019. We compared results with limits. Two Beckman Coulter DXI-800 (Minnesota, USA) autoanalysers’ results were used. We calculated the RCV values using the classical Fraser method, logarithmic Lund Method, and Clinical Laboratory Standards Institute (CLSI) method as Minimal Difference (MD). We found the same permissible measurement uncertainty limit as 15.97% for all five tumor markers. The highest RCV value was found as 90% upstream for AFP test with Lund logarithmic approach, the lowest RCV value was found as 12% for CEA with MD, all other RCV results were between these two values. We do not recommend the use of MD, as values for Biological variation are not used in the MD approach. We also recommend using the logarithmic approach, although it gives higher results. There are also clinical studies on the significance of tumor markers in a follow-up that show different results. These differences may be because the studies are conducted with different systems. Therefore, each laboratory needs to calculate its own RCV values. We also recommend informing the clinicians about the tests with high measurement uncertainty.

16 March 2022 in Turkish Journal of Pediatric Disease
Verified
Journal Article
Open access
PDF file
BDBeril Di̇lber
Beril Di̇lber
NYNihal Yıldız
Nihal Yıldız
HYHüseyin Yaman
Hüseyin Yaman
TKTulay Kamasak
Tulay Kamasak
GEGülnur Esenülkü
Gülnur Esenülkü
ACAli Cansu
Ali Cansu
Objective: We aimed this study, investigated the changes in pre- and post-treatment hematological parameters, liver and kidney function parameters in children that were diagnosed with epilepsy and initiated on levetiracetam (LEV) therapy. Methodology: The study population consisted of 114 children (6-18 years) had normal growth percentiles, that were treated for new-onset epilepsy with LEV monotherapy. In each patient, hematological parameters, B12, ferritin, liver and kidney function parameters were measured before and one/three years after the initiation of the therapy. Results: The hemoglobin (Hgb) and hematocrit (Htc) levels showed a significant increase and the absolute lymphocyte count (ALC), absolute neutrophil count (ANC) (p=0.000), monocyte percentage (p=0.032), and mean platelet volume (MPV) (p=0.000) levelsshowed a significant decrease. The ALC levels decreased significantly in 6 (5.3%) children. The mean drug dose at three years of treatment was 30.0±5.6 mg/kg/day. No significant difference was found between pre- and post-treatment platelet (PLT) counts and no significant correlation was found between gender and hematological parameters (p>0.05 for both). Conclusion: Although LEV monotherapy led to changes in the hematological parameters of the epilepsy patients, no significant change was observed in liver function. We suggest that when evaluating the hematological parameters in children with epilepsy, the community’s predisposition should be considered and also children should be examined for iron deficiency and vitamin B12 deficiency anemia before initiating the LEV therapy. It was also revealed that long-term LEV monotherapy is a safe treatment in children with epilepsy.

30 April 2021 in Journal of Academic Research in Medicine
Verified
Journal Article
Closed access
ESElif Sağ
Elif Sağ
EÖEmine Esra Öztürk
Emine Esra Öztürk
HCHatice Sonay Yalçın Cömert
Hatice Sonay Yalçın Cömert
YAYakup Arslan
Yakup Arslan
SKSüleyman Caner Karahan
Süleyman Caner Karahan
MÇMurat ÇAKIR
Murat ÇAKIR